Article Information
History
- January 30, 2021.
Article Versions
- Version 1 (January 28, 2021 - 17:39).
- You are currently viewing Version 2 of this article (January 30, 2021 - 20:42).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Weitong Yao1,2,
- Yifei Wang1,
- Danting Ma1,
- Xiaojuan Tang1,2,
- Haimin Wang1,
- Chao Li1,
- Hua Lin3,
- Yujun Li1,* and
- Guocai Zhong1,2,*
- 1Shenzhen Bay Laboratory, Shenzhen 518132, China
- 2School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China
- 3Biomedical Research Center of South China, Fujian Normal University, Fuzhou 350117, China
- ↵*Corresponding author. Email: liyj{at}szbl.ac.cn; zhonggc{at}szbl.ac.cn
Posted January 30, 2021.
Circulating SARS-CoV-2 variants B.1.1.7, 501Y.V2, and P.1 have gained ability to utilize rat and mouse Ace2 and altered in vitro sensitivity to neutralizing antibodies and ACE2-Ig
